logo

David Wohl, MD

David Wohl, MD

Infectious Disease Pinehurst, NC

Associate Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine

Office Address

Office Map
  • 155 Memorial Dr
    Pinehurst, NC 28374
    Phone: (910) 715-1000
    Fax: (910) 715-1926

Dr. Wohl's Clinical Specialties & Interests

  • Infectious Disease: General Infectious Disease

Dr. Wohl's Education & Medical Training

  • University of North Carolina HospitalsUniversity of North Carolina HospitalsFellowship, Infectious Disease
  • Duke University HospitalDuke University HospitalResidency, Internal Medicine
  • Rutgers Robert Wood Johnson Medical SchoolRutgers Robert Wood Johnson Medical SchoolMedical School

Dr. Wohl's Certifications & Licensure

  • NC State Medical LicenseNC State Medical License1994 - 2014
  • American Board of Internal MedicineAmerican Board of Internal MedicineInternal Medicine
  • American Board of Internal MedicineAmerican Board of Internal MedicineInfectious Disease

Dr. Wohl's Publications & Presentations

PubMed | Citations by Web of Science®

Grant Support

  • RCT Of An Augmented Test, Treat, Link, &Retain Model For NC And Texas Prisoners
    RCT Of An Augmented Test, Treat, Link, &Retain Model For NC And Texas PrisonersNational Institute On Drug Abuse
    2010 - 2011
  • Clinical Trial: Two Doses Of Gw433908/Ritonavir Given With Abacavir/Lamivudine C
    Clinical Trial: Two Doses Of Gw433908/Ritonavir Given With Abacavir/Lamivudine CNational Center For Research Resources
    2008 - 2008
  • Clinical Trial: Phase I/II Uridine Supplementation In HIV Lipoatrophy (Actg A522
    Clinical Trial: Phase I/II Uridine Supplementation In HIV Lipoatrophy (Actg A522National Center For Research Resources
    2008 - 2008
  • Clinical Trial: A5235 - Minocycline In The Treatment Of Hiv-Associated Cognitive
    Clinical Trial: A5235 - Minocycline In The Treatment Of Hiv-Associated CognitiveNational Center For Research Resources
    2008 - 2008
  • Clinical Trial: Enfurvitide (T-20) Intensification For Low Level Viremia (The Lo
    Clinical Trial: Enfurvitide (T-20) Intensification For Low Level Viremia (The LoNational Center For Research Resources
    2008 - 2008
  • Clinical Trial: MRK AD5 HIV-1 GAG Vaccine In HIV-1 Subjects WHO Interupt Therapy
    Clinical Trial: MRK AD5 HIV-1 GAG Vaccine In HIV-1 Subjects WHO Interupt TherapyNational Center For Research Resources
    2008 - 2008
  • Enfurvitide (T-20) Intensification For Low Level Viremia (The Lola Study)
    Enfurvitide (T-20) Intensification For Low Level Viremia (The Lola Study)National Center For Research Resources
    2007 - 2007
  • Incarceration And Hiv-Infected Inmates
    Incarceration And Hiv-Infected InmatesNational Institute Of Mental Health
    2007 - 2010
  • Phase 3 Comparison Of Lopinavir/Ritonavir Efavirenz Stavudine Lamivudine For Ini
    Phase 3 Comparison Of Lopinavir/Ritonavir Efavirenz Stavudine Lamivudine For IniNational Center For Research Resources
    2007 - 2007
  • Phase I/II Uridine Supplementation In HIV Lipoatrophy (Actg A5229)
    Phase I/II Uridine Supplementation In HIV Lipoatrophy (Actg A5229)National Center For Research Resources
    2007 - 2007
  • Two Doses Of Gw433908/Ritonavir Given With Abacavir/Lamivudine Combo
    Two Doses Of Gw433908/Ritonavir Given With Abacavir/Lamivudine ComboNational Center For Research Resources
    2006 - 2007
  • Long-Term Antiviral Management Of HCV And HIV-1 Coinfected Subjects (Slam-C)
    Long-Term Antiviral Management Of HCV And HIV-1 Coinfected Subjects (Slam-C)National Center For Research Resources
    2006 - 2008
  • Ezetimibe Therapy For Dyslipidemia In Patients Receiving HIV Therapy
    Ezetimibe Therapy For Dyslipidemia In Patients Receiving HIV TherapyNational Center For Research Resources
    2006 - 2007
  • MRK AD5 HIV-1 GAG Vaccine In HIV-1 Subjects WHO Interupt Therapy
    MRK AD5 HIV-1 GAG Vaccine In HIV-1 Subjects WHO Interupt TherapyNational Center For Research Resources
    2006 - 2007
  • Fat Redistribution And Metabolic Change In HIV Infection
    Fat Redistribution And Metabolic Change In HIV InfectionNational Center For Research Resources
    2005 - 2008
  • Nutriceuticals D-Glucarate, Silymarin And Piperine On Pharmacokinetics
    Nutriceuticals D-Glucarate, Silymarin And Piperine On PharmacokineticsNational Center For Research Resources
    2005 - 2007
  • Combination Therapy With Fish Oil Supplement And Fenofibrate
    Combination Therapy With Fish Oil Supplement And FenofibrateNational Center For Research Resources
    2005 - 2006
  • Fish Oil Supplementation PLUS Diet And Excercise VS Diet And Exercise Alone-Hiv
    Fish Oil Supplementation PLUS Diet And Excercise VS Diet And Exercise Alone-HivNational Center For Research Resources
    2005 - 2005
  • Antiretroviral Switch At Lower VS Higher HIV-1 RNA Levels With Relapse
    Antiretroviral Switch At Lower VS Higher HIV-1 RNA Levels With RelapseNational Center For Research Resources
    2005 - 2006
  • Potent Combo Antiretroviral Regimen In AA Men And Women
    Potent Combo Antiretroviral Regimen In AA Men And WomenNational Center For Research Resources
    2005 - 2005
  • ACTG A5142
    ACTG A5142National Center For Research Resources
    2004 - 2006
  • Metformin And Rosiglitazone Alone Or In Combination In Hiv-Infected Subjects
    Metformin And Rosiglitazone Alone Or In Combination In Hiv-Infected SubjectsNational Center For Research Resources
    2004 - 2005
  • Immune Response To Pneumococcal Vaccine In Patients With HIV
    Immune Response To Pneumococcal Vaccine In Patients With HIVNational Center For Research Resources
    2004 - 2005
  • Fish Oil Supplementation PLUS Diet And Excercise Vs. Diet And Exercise Alone-Hiv
    Fish Oil Supplementation PLUS Diet And Excercise Vs. Diet And Exercise Alone-HivNational Center For Research Resources
    2004 - 2004
  • Valganciclovir Pre-Emptive Therapy For CMV Viremia  (Actg A5030)
    Valganciclovir Pre-Emptive Therapy For CMV Viremia (Actg A5030)National Center For Research Resources
    2004 - 2006
  • Combinations Of Potent Antiretroviral Therapy, Hiv-Specific Immunizations
    Combinations Of Potent Antiretroviral Therapy, Hiv-Specific ImmunizationsNational Center For Research Resources
    2004 - 2004
  • Antiretroviral Switch At Lower Vs. Higher HIV-1 RNA Levels With Relapse
    Antiretroviral Switch At Lower Vs. Higher HIV-1 RNA Levels With RelapseNational Center For Research Resources
    2004 - 2004
  • Phase II Once-Weekly Alendronate In Hiv-Infected Subjects With Decreased Bone D
    Phase II Once-Weekly Alendronate In Hiv-Infected Subjects With Decreased Bone DNational Center For Research Resources
    2004 - 2007
  • Potent Combination Of Antiretroviral Regimen In African-American Men And Women
    Potent Combination Of Antiretroviral Regimen In African-American Men And WomenNational Center For Research Resources
    2004 - 2007
  • HIV+ Prison Releases To Access To HIV Care And Services
    HIV+ Prison Releases To Access To HIV Care And ServicesNational Institute On Drug Abuse
    2003 - 2007
  • Trial Of Salvage Antiretroviral Therapies For HIV PTS
    Trial Of Salvage Antiretroviral Therapies For HIV PTSNational Center For Research Resources
    2000 - 2000
  • Ddl/D4t/Hu VS Ddl/D4t/Efv VS Protease Inhibitor In HIV PTS
    Ddl/D4t/Hu VS Ddl/D4t/Efv VS Protease Inhibitor In HIV PTSNational Center For Research Resources
    2000 - 2000
  • HIV &Cmv &Development Of CMV End-Organ Disease
    HIV &Cmv &Development Of CMV End-Organ DiseaseNational Center For Research Resources
    2000 - 2000
  • Thalidomide For Recurrent Aphthous Stomatitis In HIV
    Thalidomide For Recurrent Aphthous Stomatitis In HIVNational Center For Research Resources
    2000 - 2000
  • The Longitudinal Study Of Ocular Complications Of AIDS
    The Longitudinal Study Of Ocular Complications Of AIDSNational Center For Research Resources
    2000 - 2000
  • Abt378/Ritonavir W/ Reverse Transcriptase Inhibitors In HIV
    Abt378/Ritonavir W/ Reverse Transcriptase Inhibitors In HIVNational Center For Research Resources
    2000 - 2000
  • A Longitudinal Study Of Quantitative CMV In Pys W/ AIDS
    A Longitudinal Study Of Quantitative CMV In Pys W/ AIDSNational Center For Research Resources
    2000 - 2000
  • Ganciclovir Cidofovir CMV Retinitis Trial
    Ganciclovir Cidofovir CMV Retinitis TrialNational Center For Research Resources
    1999 - 2002
  • ACTG 379 Discontinuing Maintenance Therapy For CMV Retinitis
    ACTG 379 Discontinuing Maintenance Therapy For CMV RetinitisNational Center For Research Resources
    1999 - 2002
  • Thalidomide For Treatment Of Recurrent Aphthous Ulcers In HIV
    Thalidomide For Treatment Of Recurrent Aphthous Ulcers In HIVNational Center For Research Resources
    1999 - 2002
  • NCI AIDS Related Cancer Cohort Study (ACCS)
    NCI AIDS Related Cancer Cohort Study (ACCS)National Center For Research Resources
    1999 - 2002
  • HIV And CMV Viral Burden And Development Of CMV End-Organ Disease
    HIV And CMV Viral Burden And Development Of CMV End-Organ DiseaseNational Center For Research Resources
    1998 - 2002
  • Investigational New Drug Application For HIV
    Investigational New Drug Application For HIVNational Center For Research Resources
    1998 - 1999
  • A Longitudinal Study Of The Predictive Value Of Quantitative CMV
    A Longitudinal Study Of The Predictive Value Of Quantitative CMVNational Center For Research Resources
    1997 - 2002

Hospital Affiliations

Insurance Accepted

  • BCBS Blue Card PPO
  • BCBS North Carolina BlueOptions PPO
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • Great West PPO
  • Humana ChoiceCare Network PPO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO

Alternate Names

  • Dr. David Wohl, Dr. David Wohl, MD, Dr. D Wohl, Dr. David A Wohl

15 Colleague Invites!
Is this you? If so, register to see 15 messages.

Physicians, view Dr. Wohl's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV